Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019
Copyright © 2021 Elsevier Ltd. All rights reserved..
Severe Coronavirus Disease 2019 (COVID-19) is characterized by numerous complications, complex disease, and high mortality, making its treatment a top priority in the treatment of COVID-19. Integrated traditional Chinese medicine (TCM) and western medicine played an important role in the prevention, treatment, and rehabilitation of COVID-19 during the epidemic. However, currently there are no evidence-based guidelines for the integrated treatment of severe COVID-19 with TCM and western medicine. Therefore, it is important to develop an evidence-based guideline on the treatment of severe COVID-19 with integrated TCM and western medicine, in order to provide clinical guidance and decision basis for healthcare professionals, public health personnel, and scientific researchers involved in the diagnosis, treatment, and care of COVID-19 patients. We developed and completed the guideline by referring to the standardization process of the "WHO handbook for guideline development", the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, and the Reporting Items for Practice Guidelines in Healthcare (RIGHT).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
Pharmacological research - 174(2021) vom: 15. Dez., Seite 105955 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Zhi-Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.12.2021 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phrs.2021.105955 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332536270 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332536270 | ||
| 003 | DE-627 | ||
| 005 | 20231225215754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2021.105955 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332536270 | ||
| 035 | |a (NLM)34715330 | ||
| 035 | |a (PII)S1043-6618(21)00539-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Zhi-Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2021 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Severe Coronavirus Disease 2019 (COVID-19) is characterized by numerous complications, complex disease, and high mortality, making its treatment a top priority in the treatment of COVID-19. Integrated traditional Chinese medicine (TCM) and western medicine played an important role in the prevention, treatment, and rehabilitation of COVID-19 during the epidemic. However, currently there are no evidence-based guidelines for the integrated treatment of severe COVID-19 with TCM and western medicine. Therefore, it is important to develop an evidence-based guideline on the treatment of severe COVID-19 with integrated TCM and western medicine, in order to provide clinical guidance and decision basis for healthcare professionals, public health personnel, and scientific researchers involved in the diagnosis, treatment, and care of COVID-19 patients. We developed and completed the guideline by referring to the standardization process of the "WHO handbook for guideline development", the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, and the Reporting Items for Practice Guidelines in Healthcare (RIGHT) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Guideline | |
| 650 | 4 | |a Integrated Chinese and western medicine | |
| 650 | 4 | |a Traditional Chinese medicine | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
| 700 | 1 | |a Xie, Zhi-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Hai-Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jian-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Xiang-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shou-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jiao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Juan-Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Qiang-Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qiu-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yue-Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Dian-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xiao-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Si-Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Wei-Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yi-Ni |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Feng-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Wen-Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xia-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ke-Er |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Ming-Qian |e verfasserin |4 aut | |
| 700 | 1 | |a He, Yuan-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Xi, An-Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yao-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Cheng-Ping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological research |d 1992 |g 174(2021) vom: 15. Dez., Seite 105955 |w (DE-627)NLM012597384 |x 1096-1186 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2021 |g day:15 |g month:12 |g pages:105955 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phrs.2021.105955 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2021 |b 15 |c 12 |h 105955 | ||